Ovarian cancer/Fallopian Tube cancer/Primary Peritoneal cancer: Useful in certain circumstances…Pembrozilumab (for microsatellite instability-high [MSI-H] or mismatch repair-deficient [dMMR] solid tumors, or patients with tumor mutational burden-high [TMB-H] tumors ≥10 mutations/ megabase and no satisfactory alternative treatment options).

Merck...announced that the European Commission has approved KEYTRUDA, Merck’s anti-PD-1 therapy, as monotherapy for the treatment of microsatellite instability-high (MSI-H) or deficient mismatch repair (dMMR) tumors in adults with...unresectable or metastatic gastric, small intestine or biliary cancer, who have disease progression on or following at least one prior therapy.

The results demonstrated microsatellite instability-high (MSI-H) and BRCA1/2 negative….The patient was then treated with pembrolizumab (200 mg every 3 weeks) and nab-paclitaxel (260 mg/m2) from December 2018. After 6 cycles of therapy, in April 2019, PET/CT revealed complete response in the left liver (Fig. 1)...